Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin add-on to metformin in type 2 diabetes with inadequate glycemic control
2006-001392-37Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Metformin + sitagliptin with Metformin + placebo (2 arms). Primary endpoint: Change in HbA1c at 18 weeks. Started Jun 2006; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-001392-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001392-37.